Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anton Klingler
Observed names:
A Klingler,
Klingler, Anton
Observed institutions:
Innsbruck Medical University,
Universität Innsbruck,
Intercell (Austria)
OpenAlex ID:
A5065358331
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
2007
·
E Tauber
, H Kollaritsch
, et al.
·
The Lancet
·
195
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial
2020
·
Nina Wressnigg
, Romana Hochreiter
, et al.
·
The Lancet Infectious Diseases
·
110
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial
2020
·
Christopher Adlbrecht
, Raphael Wurm
, et al.
·
Critical Care
·
85
PDF
A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
2017
·
Jordi Rello
, Claus-Georg Krenn
, et al.
·
Critical Care
·
82
PDF
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults
2023
·
Nicole Bézay
, Romana Hochreiter
, et al.
·
The Lancet Infectious Diseases
·
45
Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®
2011
·
Elisabeth Schuller
, Anton Klingler
, et al.
·
Vaccine
·
44
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
2024
·
Nicole Bézay
, Laura Wagner
, et al.
·
The Lancet Infectious Diseases
·
33
Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up
2010
·
Katrin Dubischar-Kastner
, Astrid Kaltenboeck
, et al.
·
Vaccine
·
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
2024
·
Santhosh Kumar Ghadge
, Martina Schneider
, et al.
·
The Lancet Infectious Diseases
·
23
Development of a Single-Shot Live-Attenuated Chikungunya Vaccine: A Phase 1 Randomized Clinical Trial in Healthy Adults
2019
·
Nina Wressnigg
, Romana Hochreiter
, et al.
·
SSRN Electronic Journal
Additional file 1: of A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
2017
·
Rello, Jordi
, Claus-Georg Krenn
, et al.
·
Figshare
Additional file 2: of A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
2017
·
Rello, Jordi
, Claus-Georg Krenn
, et al.
·
Figshare
Additional file 1: of A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
2017
·
Rello, Jordi
, Krenn, Claus-Georg
, et al.
·
Figshare
Additional file 2: of A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
2017
·
Rello, Jordi
, Krenn, Claus-Georg
, et al.
·
Figshare
Show more works
View as search
Works count:
17
Citation count:
650
H-index:
9
I10-index:
9
Year
Topic
Type
